Abstract
The current recommendation for the duration of treatment of patients infected with chronic hepatitis C virus (HCV) genotype 1 is 48 weeks; however, the standard regimen of peginterferon plus ribavirin bears significant adverse effects, which make completion of treatment exceedingly difficult. Reported here are 2 cases of HIV-HCV-coinfected genotype-1 patients who discontinued treatment early (after 3 and 8 weeks) because of adverse effects yet had a sustained virologic response with undetectable HCV viral loads at follow-up.
MeSH terms
-
Adult
-
Antiviral Agents / administration & dosage
-
Antiviral Agents / therapeutic use*
-
Drug Administration Schedule
-
Drug Therapy, Combination
-
Genotype
-
HIV Infections / complications*
-
Hepacivirus / classification
-
Hepacivirus / drug effects
-
Hepacivirus / genetics
-
Hepacivirus / isolation & purification*
-
Hepatitis C, Chronic / complications*
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / virology
-
Humans
-
Interferon alpha-2
-
Interferon-alpha / administration & dosage
-
Interferon-alpha / therapeutic use*
-
Male
-
Middle Aged
-
Polyethylene Glycols
-
RNA, Viral / blood
-
Recombinant Proteins
-
Ribavirin / administration & dosage
-
Ribavirin / therapeutic use*
-
Time Factors
-
Treatment Outcome
-
Viral Load
Substances
-
Antiviral Agents
-
Interferon alpha-2
-
Interferon-alpha
-
RNA, Viral
-
Recombinant Proteins
-
Polyethylene Glycols
-
Ribavirin
-
peginterferon alfa-2b